The market has not factored in the ability of pathology...

The market has not factored in the ability of pathology companies to reduce their cost base by further rationalising their over-abundant collection centre numbers, as well as the risk that these changes don't pass the Senate or do so in a modified form.

CAJ has already announced the changes to radiology will have a 4-7% revenue impact based on the ages of patients they see (ie. under 16 or not), concession status and geographic location - not entirely impossible to deal with. They have also signalled the possibility of recouping lost revenue by charging patients private fees - let the politics begin, this will give lobby groups something to work with as it shows how the end user (ie. the patient), could be adversely affected by rising costs, and contrary to what the government is saying in that these changes won't affect consumers just big businesses.